Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma

PURPOSE: About 65% to 70% of melanomas harbor a mutation in v-raf murine sarcoma viral oncogene homolog B1 (BRAF) that causes the steady-state activation of extracellular signal-regulated kinase (ERK). We sought to investigate the efficacy of PLX4032 (BRAF inhibitor) to identify patterns/predictors...

ver descrição completa

Detalhes bibliográficos

Principais autores:	William D. Tap, Ke-Wei Gong, Judy Daring, Yiou Tseng, Charles Ginther, Giovanni Pauletti, John A. Glaspy, Richard Essner, Gideon Bollag, Peter Hirth, Chao Zhang, Dennis J. Slamon
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2010-08-01
coleção:	Neoplasia: An International Journal for Oncology Research
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S147655861080065X
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!